EGFR and neoplasm: Furthermore, the combination of gefitinib, an epidermal growth factor receptor inhibitor, and lenvatinib, an anti-tumour angiogenesis TKI, displayed potent anti-proliferative effects in epidermal growth factor receptor-expressing HCC cell lines in vitro.